PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 18, 2020Journal of Allergy and Clinical Immunology209 citationsOpen Access

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

FRFlorence RoufosseJKJean‐Emmanuel KahnMRMarc E. Rothenberg

Key Points

  • To evaluate the efficacy and safety of mepolizumab in patients with hypereosinophilic syndrome (HES).
  • Phase III, randomized, placebo-controlled trial design
  • Comparison of mepolizumab with placebo
  • Assessment of flare occurrences and safety signals
  • Mepolizumab significantly reduced the occurrence of flares compared to placebo
  • No new safety signals were identified during the trial

Abstract

Compared with placebo, mepolizumab significantly reduced the occurrence of flares in patients with HES, with no new safety signals identified.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Roufosse et al. (2020) studied this question.

synapsesocial.com/papers/69dacd90aae38ff6ad836b88https://doi.org/10.1016/j.jaci.2020.08.037
Ask AI
Helpful
Bookmark
Share
View Full Paper